TY - JOUR
KW - Adult
KW - Aged
KW - Attitude of Health Personnel
KW - Buprenorphine/administration & dosage
KW - Female
KW - Health Care Surveys
KW - Humans
KW - Male
KW - Medicaid
KW - Middle Aged
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/rehabilitation
KW - Patient Protection and Affordable Care Act
KW - Perception
KW - Physicians/statistics & numerical data
KW - United States
KW - Affordable Care Act
KW - buprenorphine
KW - Health Reform
KW - physician survey
KW - substance use disorder treatment delivery
AU - H. K. Knudsen
AU - J. L. Studts
A1 - 
AB - The Affordable Care Act (ACA) has been heralded as a major policy change that is expected to transform the delivery of substance use disorder (SUD) treatment. Few studies have reported on the perceived impacts of ACA from the perspectives of SUD treatment providers, such as physicians who prescribe buprenorphine to patients with opioid use disorder. The present study describes buprenorphine prescribers' perceptions regarding impacts of the ACA on the delivery of buprenorphine and examines whether state-level approaches to implementing ACA are associated with its perceived impacts. Data are drawn from a national sample of current buprenorphine prescribers (n = 1,174) who were surveyed by mail. On average, buprenorphine prescribers reported ambivalence regarding the impacts of the ACA, as indicated by a mean of 2.75 (SD = 0.69) on a scale that ranged from 1 ("strongly disagree") to 5 ("strongly agree"). A multi-level mixed-effects regression model indicated that physicians practicing in states that were supportive of ACA, as indicated by adopting both the Medicaid expansion and implementing a state-based health insurance exchange, had more positive perceptions of the ACA than physicians in states that had declined both of these policies. This study suggests that state approaches to ACA may be associated with varied impacts.
AD - a Associate Professor, Center on Drug and Alcohol Research , University of Kentucky , Lexington , KY , USA.; b Associate Professor, Department of Behavioral Science , University of Kentucky , Lexington , KY , USA.; b Associate Professor, Department of Behavioral Science , University of Kentucky , Lexington , KY , USA.
BT - Journal of psychoactive drugs
C5 - Healthcare Policy; Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1080/02791072.2017.1295335
IS - 2
JF - Journal of psychoactive drugs
M1 - Journal Article
N2 - The Affordable Care Act (ACA) has been heralded as a major policy change that is expected to transform the delivery of substance use disorder (SUD) treatment. Few studies have reported on the perceived impacts of ACA from the perspectives of SUD treatment providers, such as physicians who prescribe buprenorphine to patients with opioid use disorder. The present study describes buprenorphine prescribers' perceptions regarding impacts of the ACA on the delivery of buprenorphine and examines whether state-level approaches to implementing ACA are associated with its perceived impacts. Data are drawn from a national sample of current buprenorphine prescribers (n = 1,174) who were surveyed by mail. On average, buprenorphine prescribers reported ambivalence regarding the impacts of the ACA, as indicated by a mean of 2.75 (SD = 0.69) on a scale that ranged from 1 ("strongly disagree") to 5 ("strongly agree"). A multi-level mixed-effects regression model indicated that physicians practicing in states that were supportive of ACA, as indicated by adopting both the Medicaid expansion and implementing a state-based health insurance exchange, had more positive perceptions of the ACA than physicians in states that had declined both of these policies. This study suggests that state approaches to ACA may be associated with varied impacts.
PP - United States
PY - 2017
SN - 2159-9777; 0279-1072
SP - 111
EP - 121
EP - 
T1 - Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers
T2 - Journal of psychoactive drugs
TI - Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers
U1 - Healthcare Policy; Opioids & Substance Use
U2 - 28296579
U3 - 10.1080/02791072.2017.1295335
VL - 49
VO - 2159-9777; 0279-1072
Y1 - 2017
Y2 - Apr-Jun
ER -